Takeda has co-launched Outpost Medicine, which will focus on therapies for urologic and gynaecologic conditions following a $41m funding round that included Novo.
Japan-based pharmaceutical company Takeda Pharmaceutical and US-based investment firm Frazier Healthcare Partners co-launched a biopharmaceutical company called Outpost Medicine on Monday with $41m of funding.
Frazier led the series A round, which included contributions from pharmaceutical company Novo, private equity firm Adams Street Partners and investment firm Vivo Capital.
Outpost Medicine has secured an exclusive license from Takeda to develop and commercialise a clinical stage drug candidate for stress urinary incontinence, a condition that results in unintentional loss of urine…
